{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine with or without aura in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 69, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 6948244, "fmt": "6.95M", "longFmt": "6,948,244"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43528872, "fmt": "43.53M", "longFmt": "43,528,872"}}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 3998042, "fmt": "4M", "longFmt": "3,998,042"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 13150419, "fmt": "13.15M", "longFmt": "13,150,419"}}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2972736, "fmt": "2.97M", "longFmt": "2,972,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5172329, "fmt": "5.17M", "longFmt": "5,172,329"}}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 60, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2576755, "fmt": "2.58M", "longFmt": "2,576,755"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 28534760, "fmt": "28.53M", "longFmt": "28,534,760"}}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 54, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2983231, "fmt": "2.98M", "longFmt": "2,983,231"}, "exercisedValue": {"raw": 2777988, "fmt": "2.78M", "longFmt": "2,777,988"}, "unexercisedValue": {"raw": 10864175, "fmt": "10.86M", "longFmt": "10,864,175"}}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 61, "title": "Senior VP & Chief Scientific Officer of Global Research", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Perry C. Siatis", "age": 48, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1975, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "SVP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1121841, "fmt": "1.12M", "longFmt": "1,121,841"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1709078400, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 178.99, "open": 179.85, "dayLow": 176.89, "dayHigh": 179.89, "regularMarketPreviousClose": 178.99, "regularMarketOpen": 179.85, "regularMarketDayLow": 176.89, "regularMarketDayHigh": 179.89, "dividendRate": 6.2, "dividendYield": 0.0348, "exDividendDate": 1712880000, "payoutRatio": 2.1764998, "fiveYearAvgDividendYield": 4.47, "beta": 0.542, "trailingPE": 65.44118, "forwardPE": 14.578215, "volume": 4326102, "regularMarketVolume": 4326102, "averageVolume": 5439223, "averageVolume10days": 4810770, "averageDailyVolume10Day": 4810770, "bid": 176.58, "ask": 0.0, "bidSize": 800, "askSize": 800, "marketCap": 314431668224, "fiftyTwoWeekLow": 130.96, "fiftyTwoWeekHigh": 179.89, "priceToSalesTrailing12Months": 5.7887197, "fiftyDayAverage": 165.3522, "twoHundredDayAverage": 149.29504, "trailingAnnualDividendRate": 5.99, "trailingAnnualDividendYield": 0.033465553, "currency": "USD", "fromCurrency": null, "toCurrency": null, "lastMarket": null, "coinMarketCapLink": null, "algorithm": null, "tradeable": false, "enterpriseValue": 362232250368, "profitMargins": 0.08953, "floatShares": 1762410470, "sharesOutstanding": 1766470016, "sharesShort": 14748988, "sharesShortPriorMonth": 13561430, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0083, "heldPercentInsiders": 0.00153, "heldPercentInstitutions": 0.72047997, "shortRatio": 2.83, "shortPercentOfFloat": 0.0084, "impliedSharesOutstanding": 1766470016, "category": null, "bookValue": 5.867, "priceToBook": 30.339184, "fundFamily": null, "legalType": null, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.668, "netIncomeToCommon": 4819999744, "trailingEps": 2.72, "forwardEps": 12.21, "pegRatio": 4.87, "lastSplitFactor": null, "enterpriseToRevenue": 6.669, "enterpriseToEbitda": 13.743, "52WeekChange": 0.15941179, "SandP52WeekChange": 0.27549195, "lastDividendValue": 1.55, "lastDividendDate": 1705017600, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "messageBoardId": "finmb_141885706", "gmtOffSetMilliseconds": -18000000, "currentPrice": 178.0, "targetHighPrice": 206.0, "targetLowPrice": 153.0, "targetMeanPrice": 181.38, "targetMedianPrice": 180.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 12816000000, "totalCashPerShare": 7.255, "ebitda": 26357999616, "totalDebt": 60579000320, "quickRatio": 0.633, "currentRatio": 0.872, "totalRevenue": 54317998080, "debtToEquity": 582.658, "revenuePerShare": 30.723, "returnOnAssets": 0.08071, "returnOnEquity": 0.35204, "freeCashflow": 22628499456, "operatingCashflow": 22838999040, "earningsGrowth": -0.669, "revenueGrowth": -0.054, "grossMargins": 0.69207, "ebitdaMargins": 0.48525003, "operatingMargins": 0.31809, "financialCurrency": "USD"}